## Overview

The characterization of intact monoclonal antibodies by mass spectrometry is challenging due to the size and complexity of the molecules. The ability to separate charge variants in a separation that is directly coupled to the mass spectrometer greatly improves the MS analysis by minimizing spectral overlap of similar variants, while also providing a charge variant separation which aids in identification of the species. We have previously demonstrated the ability to do such an analysis using microfluidic capillary electrophoresis – ESI-MS under "near native conditions". This current work extends that capability by operating under fully native conditions which maintain the folded structure of the molecules both during the CE separation and through the ESI transition into the gas phase.

## Methods

All work was performed using a commercially available microfluidic CE-ESI system (ZipChip, 908 Devices Inc.), attached to an orbitrap mass spectrometer (Exactive EMR or Q Exactive HF-X Biopharma, ThermoFisher). The microfluidic devices utilized a covalently attached, neutral polymer surface coating to prevent analyte interactions and suppress electroosmotic flow. An optimal background electrolyte (BGE) was developed to maintain fully native conditions while maximizing the resolving power of the separation and the sensitivity of the ESI-MS. The method was initially tested with the NIST monoclonal antibody reference material (RM 8671, purchased from NIST), along with approved drug molecules trastuzumab, and trastuzumab emtansine (T-DM1) which were kindly provided by collaborators. All samples were diluted directly from formulation to a concentration of 1 mg/mL. No other sample prep was done. All samples were run with the same separation method. Data were processed using Biopharmafinder 1.0 (ThermoFisher).

ZipChip Method:

- High resolution chip (HR, 22 cm separation channel)
- 1 nL injection volume
- 500 V/cm
- Pressure assist enabled at 0.5 minutes
- 10 minute analysis time

Exactive EMR Mass Spec Method:

- EMR mode (HCD pressure 6)
- SID 150/CE 60
- S Lens RF: 100
- Inlet temperature 200 C
- 3 microscans

QE HF-X Biopharma Mass Spec Method:

- HMR mode (HCD pressure 1.5)
- SID 150
- Funnel RF: 100
- Inlet temperature 200 C
- 3 microscans

**Separation** Channel +2 kV \_\_\_\_\_ BGE

**Device Schematic** 

+15 kV






# Native Analysis of Monoclonal Antibodies by Microchip Capillary Electrophoresis-ESI-MS

## J. Scott Mellors<sup>1</sup> and Erin A. Redman<sup>1</sup> <sup>1</sup>908 Devices Inc., Boston, MA and Carrboro, NC


#### Native Analysis of NIST mAb 1 mg/mL NIST mAb **Exactive Plus EMR mass spec** Rs = 35,000 **Full spectra** 1K acidic 2K 4500 65 70 75 8.0 Time (min)

## Native Analysis of Trastuzumab and T-DM1

#### 1 mg/mL Trastuzumab Q Exactive HF-X Biopharma




### Mass Spec Performance




BGE

Waste





accuracy of large intact proteins, but the signal intensity decays at higher resolution glycoform resolution at a setting of 35,000. The plot above shows the deconvoluted measured mass error was 0.7 Da (~5 ppm)



Time (min)

Conjugation of drug molecules onto the structure of trastuzumab creates a very complex group of variants. Without a separation, spectral overlap impedes the mass spec's ability to see all of the drug-antibody ratio (DAR) variant peaks. The 2D map view shows how the combined power of the separation and the mass spec can resolve all of the variants.

#### Conclusions

The ZipChip platform has demonstrated the ability to resolve charge variants of native, intact mAbs and ADCs while also efficiently transferring them into the gas phase. Orbitrap mass specs with the capability of efficiently transporting large ions to the mass analyzer yield highly accurate and sensitive mass spec characterization of these ions. The peak profiles generated by the native ZipChip separation correlate very well with traditional charge variant separation techniques, such as isoelectric focusing, and ion exchange chromatography. The fast analysis times and easy set up of this system make this technology a simple and powerful addition to the biopharma toolkit.

**References:** 

1. N.G. Batz et al., Anal. Chem. 2014, 86, 3493-3500. 2. E.A. Redman et al., Anal. Chem. 2015, 87, 2264-2272. 3. E.A. Redman et al., Anal. Chem. 2016, 88, 2220-2226.

The technologies discussed in this poster are the subject of one or more granted/pending patents. www.908devices.com/patents/